Our mission is to give people with eosinophilic asthma control of their disease—and their lives

Today, our team is focused on a single goal: To develop the first oral drug for eosinophilic asthma.

Our global development team brings together experts from Knopp Biosciences, which previously developed dexpramipexole, and Population Health Partners, whose employees and executives led eight drug approvals involving 21 clinical trials and 91,000 patients worldwide in their earlier work at The Medicines Company.

Company Leaders

Jorge Bartolome

Chief Executive Officer

Peter Wijngaard, Ph.D.

Chief Development Officer

Calman Prussin, M.D.

Chief Scientific Officer

Mark Kreston

Chief Commercial Officer

Christopher Courts, CPA

Chief Financial Officer

Eric Bradford, M.D.

Chief Medical Officer

Robin Walker, J.D.

Chief Legal Officer and Corporate Secretary

Dan Tokich

Head of Global Supply

Tamsin Berry

Head of Policy and Partnerships

Shannon Armstrong

Head of Evidence, Market Access and Value

Lex Kay

Head of Global Quality

Richard Fires

Head of Human Resources

Board of Directors

Jorge Bartolome

Chief Executive Officer, areteia therapeutics

Paul Berns

Managing Director, Arch Venture Partners

Steve Butts

Chief Executive Officer, Arrivo BioVentures, LLC

Benjamin Gomez

Managing Director, Pilot House Associates

Adam Koppel, M.D., Ph.D.

Managing Partner, Bain Capital

Michael Bozik, M.D.

President, Biohaven Labs

Former Chief Executive Officer, Knopp Biosciences, LLC

Ian Read

Chairman of the Board, areteia therapeutics

Partner, Population Health Partners & Former Chair and Chief Executive Officer, Pfizer

Join Us

The Areteia team is global, agile, and outcome-driven. We value team members as both leaders and doers.